Glenmede Trust’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Glenmede Trust’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-648	Closed	-$34K	–	2552
2020 Q3	$34K	Sell	648 -64	-9%	-$3.95K	﹤0.01%	1431
2020 Q2	$43K	Sell	712 -479	-40%	-$27.7K	﹤0.01%	1349
2020 Q1	$67K	Hold	1,191	–	–	﹤0.01%	1572
2019 Q4	$67K	Hold	1,191	–	–	﹤0.01%	1572
2019 Q3	$63	Hold	1,191	–	–	﹤0.01%	1558
2019 Q2	$71	Buy	1,191 +193	+19%	+$12.1K	﹤0.01%	1535
2019 Q1	$62	Buy	998 +13	+1%	+$860	﹤0.01%	1584
2018 Q4	$59	Buy	+985	New	+$58.8K	﹤0.01%	1530

Other funds holding BSTC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Glenmede Trust's BSTC Position: Q4 2020 in Review

Glenmede Trust sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 648 shares — an estimated $34K sold.

Glenmede Trust first reported a position in BSTC in Q4 2018 and held it in 8 quarters. The position peaked at $67K in Q1 2020. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.

Glenmede Trust reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 648 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $34K.
Glenmede Trust first reported a position in BioSpecifics Technologies Corp. in Q4 2018 and held it in 8 quarters.
Glenmede Trust's BioSpecifics Technologies Corp. position peaked at $67K in Q1 2020.
1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.